EcoDrugPlus

Transcription Factor P65-Like

Ensembl ID : ENSPFOG00000009881
Gene Symbol: LOC103140625
3 Cross references
199 Possible Orthologues:

Transforming Growth Factor, Beta Receptor 1 B

Ensembl ID : ENSPFOG00000000324
Gene Symbol: TGFBR1B
1 Cross references
204 Possible Orthologues:

Transient Receptor Potential Cation Channel, Subfamily A, Member 1b

Ensembl ID : ENSPFOG00000012739
Gene Symbol: TRPA1B
1 Cross references
200 Possible Orthologues:

Tryptophan 5-Hydroxylase 1-Like

Ensembl ID : ENSPFOG00000011276
Gene Symbol: LOC103149204
3 Cross references
176 Possible Orthologues:

Tryptophan Hydroxylase 1

Ensembl ID : ENSPFOG00000024080
Gene Symbol: TPH1
3 Cross references
207 Possible Orthologues:

Tubulin Alpha 4a

Ensembl ID : ENSPFOG00000002295
Gene Symbol: TUBA4A
3 Cross references
110 Possible Orthologues:

Tubulin Alpha-1b Chain-Like

Ensembl ID : ENSPFOG00000008025
Gene Symbol: LOC103156799
2 Cross references
37 Possible Orthologues:

Tubulin Beta-1 Chain-Like

Ensembl ID : ENSPFOG00000007931
Gene Symbol: LOC103153835
2 Cross references
11 Possible Orthologues:

Tubulin Beta-2a Chain-Like

Ensembl ID : ENSPFOG00000000911
Gene Symbol: LOC103143005
3 Cross references
305 Possible Orthologues:

Tubulin Beta-4b Chain-Like

Ensembl ID : ENSPFOG00000003991
Gene Symbol: LOC103145779
2 Cross references
12 Possible Orthologues:

Tubulin Beta-4b Chain-Like

Ensembl ID : ENSPFOG00000010277
Gene Symbol: LOC103140028
2 Cross references
12 Possible Orthologues:

Tubulin Beta-6 Chain

Ensembl ID : ENSPFOG00000004579
Gene Symbol: LOC103135551
3 Cross references
184 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).